FDA approves first genetic test to help identify risk of developing opioid use disorder
Fuente:
Wiley Open Access
Gespeichert in:
| Format: | Artículo Open Access |
|---|---|
| Veröffentlicht: |
Wiley
2024
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867018091219648512 |
|---|---|
| collection | Wiley Open Access |
| contents | FDA approves first genetic test to help identify risk of developing opioid use disorder The Brown University Child & Adolescent Psychopharmacology Update On Dec. 19, 2023, the U.S. Food and Drug Administration approved the first test that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD). As part of a clinical evaluation, the AutoGenomics, Inc. AvertD test is intended to be used prior to first exposure to oral opioid pain medications in patients being considered for a 4–30‐day prescription for the treatment of acute pain, such as in patients scheduled to undergo a planned surgical procedure. 10.1002/cpu30840 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/cpu30840 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_cpu30840 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | FDA approves first genetic test to help identify risk of developing opioid use disorder The Brown University Child & Adolescent Psychopharmacology Update FDA approves first genetic test to help identify risk of developing opioid use disorder The Brown University Child & Adolescent Psychopharmacology Update On Dec. 19, 2023, the U.S. Food and Drug Administration approved the first test that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD). As part of a clinical evaluation, the AutoGenomics, Inc. AvertD test is intended to be used prior to first exposure to oral opioid pain medications in patients being considered for a 4–30‐day prescription for the treatment of acute pain, such as in patients scheduled to undergo a planned surgical procedure. 10.1002/cpu30840 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | FDA approves first genetic test to help identify risk of developing opioid use disorder |
| topic | The Brown University Child & Adolescent Psychopharmacology Update |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cpu30840 |